Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated vs Conventional Chemoradiotherapy in LANSCLC
NCT07052669Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2025
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Median Progression-Free Survival at 2 years. Started Jul 2025; status: recruiting.
Beyond the preview
Go deeper on NCT07052669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052669.